Budding data scientist | Love data05 February 2018 at 10:07
Tamoxifen is a highly effective endocrine treatment for breast cancer in the adjuvant and metastatic settings. Data from several large randomized clinical trials indicate that tamoxifen is also valuable in the prevention of breast cancer in women at high risk for the disease. However, not all women benefit from tamoxifen, and the side effect profiles vary considerably from patient to patient.
Tamoxifen treatment promotes significant changes both in the plasma concentration of an important marker associated with an increased risk of Cardio Vascular Disease (CVD) and in functional parameters of cardiac performance in women with breast cancer who have previously undergone chemotherapy. Previous studies had also confirmed the cardiotoxic effects of chemotherapy.
Chronic use of tamoxifen significantly reduces the plasma concentrations of CVD biomarkers (CRP, Apo B, and the Apo-B/Apo-A ratio) in women with breast cancer who underwent chemotherapy. Several study suggests the need for a careful cardiovascular evaluation and the medical monitoring of women with breast cancer to reduce the morbidity and mortality associated with cancer treatment complications.
According to many studies, breast cancer is more common in women whose family members or blood relatives have also had breast cancer. This means that it is mostly genetic. Other factors like Radiation exposure, obesity, alcohol consumption, not having children, can all participate as risk factors fo....
There are multiple options available for reconstruction of the breast following breast cancer surgery (oncoplastic breast surgery) but the new form-stable highly cohesive silicone gel implants are a great option for reconstructive surgery. It’s important to understand that there is very little tissu....
Mithun Kumar
Tamoxifen is a highly effective endocrine treatment for breast cancer in the adjuvant and metastatic settings. Data from several large randomized clinical trials indicate that tamoxifen is also valuable in the prevention of breast cancer in women at high risk for the disease. However, not all women benefit from tamoxifen, and the side effect profiles vary considerably from patient to patient.
Tamoxifen treatment promotes significant changes both in the plasma concentration of an important marker associated with an increased risk of Cardio Vascular Disease (CVD) and in functional parameters of cardiac performance in women with breast cancer who have previously undergone chemotherapy. Previous studies had also confirmed the cardiotoxic effects of chemotherapy.
Chronic use of tamoxifen significantly reduces the plasma concentrations of CVD biomarkers (CRP, Apo B, and the Apo-B/Apo-A ratio) in women with breast cancer who underwent chemotherapy. Several study suggests the need for a careful cardiovascular evaluation and the medical monitoring of women with breast cancer to reduce the morbidity and mortality associated with cancer treatment complications.